Amgen
Czech affiliate of Amgen supplying biological medicines for oncology, cardiovascular and other serious diseases
Recent signals
What changed at Amgen in the last 6 months, newest first. Each line links to its public source.
- 6 Nov 2026 Public contract · Won €41k public contract from Všeobecná fakultní nemocnice v Praze: Amgen s.r.o. - 30879 - Nákup léčivých přípravků/zdravotnického materiálu smlouvy.gov.cz
- 5 Nov 2026 Public contract · Won €13k public contract from Karlovarská krajská nemocnice a.s.: Objednávka č. P43130 - Dodávky léků smlouvy.gov.cz
- 5 Nov 2026 Public contract · Won €31k public contract from Fakultní nemocnice Hradec Králové: nákup léčivých přípravků smlouvy.gov.cz
About Amgen
Amgen Česká republika, operated by Amgen s.r.o., is the Czech presence of the independent biotechnology company Amgen. The website describes its work as developing biological medicines, using living cells in production, and running clinical research for serious diseases such as cancer, heart disease, asthma and osteoporosis.
The website lists therapeutic areas of oncology, hematology, bone health, inflammation, cardiovascular disease, neurology and nephrology. Its audiences are patients, healthcare professionals and healthcare organizations; the site includes a section on transparent cooperation between medical experts, healthcare organizations and pharmaceutical companies. Specific Czech product names are not listed in the input.
The registry records the company as an s.r.o. based in Praha, founded in 2004. The website states that Amgen has operated in the Czech Republic for more than 20 years. The input does not mention hiring or additional offices.
Product: Biological medicines (biotherapeutics) for oncology, hematology, bone health, inflammation, cardiovascular, neurology and nephrology indications
Public contracts
Contracts Amgen signed since 1 Nov 2024, from the Slovak and Czech public contract registers. Values as published; amendments are not counted.
Customers
5,700 contracts with 61 buyers · 3.5B CZK + $9k
| Contracts | Value | |
|---|---|---|
| Všeobecná fakultní nemocnice v Praze | 395 | 607.1M CZK |
| Fakultní nemocnice Hradec Králové | 236 | 361.1M CZK |
| Fakultní nemocnice v Motole | 280 | 340.2M CZK |
| fFakultní nemocnice Olomouc | 556 | 263.1M CZK |
| Fakultní nemocnice Brno | 120 | 208.3M CZK |
| Fakultní Thomayerova nemocnice | 230 | 182.0M CZK |
| Fakultní nemocnice Ostrava | 137 | 179.6M CZK |
| Fakultní nemocnice u sv. Anny v Brně | 215 | 163.0M CZK |
Open public tenders for Amgen →
Latest contracts
- 6 Nov 2026 for Krajská nemocnice T. Bati, a. s. · Objednávka OZL/LEK/26/35227 · 213k CZK register
- 6 Nov 2026 for Fakultní nemocnice Olomouc · Dodávka léčiv a zdravotnického materiálu · 201k CZK register
- 6 Nov 2026 for Všeobecná fakultní nemocnice v Praze · Amgen s.r.o. - 30879 - Nákup léčivých přípravků/zdravotnického materiálu · 1.0M CZK register
- 6 Nov 2026 for Ústav hematologie a krevní transfuze Praha · Objednávka - léky · 184k CZK register
- 6 Nov 2026 for Nemocnice Písek, a.s. · Nákup zboží lékárna · 132k CZK register
- 5 Nov 2026 for Fakultní nemocnice Hradec Králové · nákup léčivých přípravků · 765k CZK register
Public tenders won
97 tenders won since 1 Jan 2024 from 31 public buyers in Czechia, worth 18.1B CZK as awarded. From EU award notices (TED) that name Amgen by its registry number.
- 2 Nov 2026 Úrazová nemocnice v Brně · Dynamický nákupní systém na dodávku léčivých přípravků · 2.3M CZK notice
- 28 Oct 2026 Fakultní nemocnice Ostrava · DODÁVKY LÉČIVÝCH PŘÍPRAVKŮ II. – zavedení dynamického nákupního systému · 940.2M CZK notice
- 21 Oct 2026 Fakultní nemocnice Hradec Králové · Léčivé přípravky s obsahem romosozumabu · 6.2M CZK notice
- 15 Oct 2026 Ústav hematologie a krevní transfuze Praha · Dynamický nákupní systém na dodávky léčivých přípravků pro ústavní část ÚHKT · 457.9M CZK notice
- 1 Oct 2026 Fakultní nemocnice Olomouc · LP s obsahem sotorasibu 2026 · 4.6M CZK notice
- 17 Sep 2026 Fakultní nemocnice u sv. Anny v Brně · L04AG10 INEBILIZUMAB - opakované · 20.3M CZK notice
Jobs at Amgen
Leadership
- Filip Harvánek · ProkuraSource: business register
- Geda Jonaitiené · Jednatel (Managing director)Source: business register
- Lukas Boris Baitsch · Jednatel (Managing director)Source: business register
- Petr Cypro · ProkuraSource: business register
- Šárka Veselá · ProkuraSource: business register
- Vanja Giljević Mareković · Jednatel (Managing director)Source: business register
- Veronika Jánská Těšická · ProkuraSource: business register
More biotech & pharma companies
Animalab
Lab equipment, research animal supply and servicing for animal facilities and research labs across Central and Eastern EuropeAnLab
Infectious-disease diagnostics and SPF laboratory rodent and rabbit supply for animal research facilities in the Czech RepublicARDEAPHARMA
Pharmaceutical solutions and contract manufacturing for pharmaceutical companies and healthcare providersAristo Pharma
Pharmaceutical company focused on women's health, gynaecology and urology, with products for doctors and patientsNew on EvolcAstra Diag
Distributor of in vitro diagnostics for laboratories and hospitals in Czechia and Slovakia, covering immunohematology, immunologyYoung companyAUMED
Develops bacterial vaccines, immunomodulators and bacteriophage therapies; sells GMP consulting and training to pharma and research bodies
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Frontend frameworks
- BootstrapHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Privacy & consent
- CookiebotHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.